GS vs. NBIX
GS (The Goldman Sachs Group, Inc.) and NBIX (Neurocrine Biosciences, Inc.) are both stocks. GS operates in Capital Markets (Financial Services), while NBIX operates in Drug Manufacturers - Specialty & Generic (Healthcare). Over the past 10 years, GS returned 24.48%/yr vs 13.16%/yr for NBIX. At a 0.29 correlation, their price movements are largely independent.
Performance
GS vs. NBIX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GS achieves a 22.08% return, which is significantly higher than NBIX's 12.64% return. Over the past 10 years, GS has outperformed NBIX with an annualized return of 24.48%, while NBIX has yielded a comparatively lower 13.16% annualized return.
GS
- 1D
- 2.62%
- 1M
- 11.72%
- YTD
- 22.08%
- 6M
- 20.84%
- 1Y
- 73.43%
- 3Y*
- 49.31%
- 5Y*
- 25.98%
- 10Y*
- 24.48%
NBIX
- 1D
- -1.81%
- 1M
- -0.97%
- YTD
- 12.64%
- 6M
- 4.55%
- 1Y
- 27.80%
- 3Y*
- 18.64%
- 5Y*
- 10.13%
- 10Y*
- 13.16%
GS vs. NBIX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
GS The Goldman Sachs Group, Inc. | 22.08% | 56.64% | 52.03% | 15.91% | -7.87% | 47.61% | 17.45% | 40.48% | -33.53% | 7.73% |
NBIX Neurocrine Biosciences, Inc. | 12.64% | 3.90% | 3.60% | 10.31% | 40.24% | -11.14% | -10.83% | 50.53% | -7.96% | 100.49% |
Correlation
The correlation between GS and NBIX is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.23 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.24 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.24 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.23 |
Correlation (All Time) Calculated using the full available price history since May 4, 1999 | 0.29 |
Fundamentals
GS:
$327.33B
NBIX:
$16.52B
GS:
$57.41
NBIX:
$6.53
GS:
18.51
NBIX:
24.46
GS:
2.40
NBIX:
0.48
GS:
3.02
NBIX:
5.27
GS:
2.66
NBIX:
4.85
GS:
$110.77B
NBIX:
$3.10B
GS:
$61.53B
NBIX:
$3.05B
GS:
$24.94B
NBIX:
$881.20M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GS vs. NBIX — Risk / Return Rank
GS
NBIX
GS vs. NBIX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for The Goldman Sachs Group, Inc. (GS) and Neurocrine Biosciences, Inc. (NBIX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GS | NBIX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.70 | ||
| Sortino ratioReturn per unit of downside risk | +1.82 | ||
| Omega ratioGain probability vs. loss probability | 1.41 | 1.19 | +0.23 |
| Calmar ratioReturn relative to maximum drawdown | 3.80 | 1.34 | +2.46 |
| Martin ratioReturn relative to average drawdown | 12.61 | 2.94 | +9.68 |
Loading charts...
Drawdowns
GS vs. NBIX - Drawdown Comparison
The maximum GS drawdown since its inception was -78.84%, smaller than the maximum NBIX drawdown of -97.21%. Use the drawdown chart below to compare losses from any high point for GS and NBIX.
Loading charts...
Drawdown Indicators
| GS | NBIX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -78.84% | -97.21% | +18.37% |
Max Drawdown (1Y)Largest decline over 1 year | -19.42% | -20.90% | +1.48% |
Max Drawdown (3Y)Largest decline over 3 years | -30.90% | -42.89% | +11.99% |
Max Drawdown (5Y)Largest decline over 5 years | -32.84% | -42.89% | +10.05% |
Max Drawdown (10Y)Largest decline over 10 years | -48.75% | -46.39% | -2.36% |
Current DrawdownCurrent decline from peak | -2.73% | -4.54% | +1.81% |
Average DrawdownAverage peak-to-trough decline | -22.65% | -43.84% | +21.19% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.84% | 9.49% | -3.65% |
Volatility
GS vs. NBIX - Volatility Comparison
The Goldman Sachs Group, Inc. (GS) has a higher volatility of 11.84% compared to Neurocrine Biosciences, Inc. (NBIX) at 9.63%. This indicates that GS's price experiences larger fluctuations and is considered to be riskier than NBIX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GS | NBIX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.84% | 9.63% | +2.21% |
Volatility (6M)Calculated over the trailing 6-month period | 23.47% | 23.91% | -0.44% |
Volatility (1Y)Calculated over the trailing 1-year period | 28.55% | 31.38% | -2.83% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 28.10% | 32.73% | -4.63% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 29.87% | 39.13% | -9.26% |
Dividends
GS vs. NBIX - Dividend Comparison
GS's dividend yield for the trailing twelve months is around 1.60%, while NBIX has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GS The Goldman Sachs Group, Inc. | 1.60% | 1.59% | 2.01% | 2.72% | 2.62% | 1.70% | 1.90% | 1.80% | 1.89% | 1.14% | 1.09% | 1.41% |
NBIX Neurocrine Biosciences, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
GS vs. NBIX - Financials Comparison
This section allows you to compare key financial metrics between The Goldman Sachs Group, Inc. and Neurocrine Biosciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GS vs. NBIX - Profitability Comparison
GS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, The Goldman Sachs Group, Inc. reported a gross profit of 16.91B and revenue of 17.23B. Therefore, the gross margin over that period was 98.2%.
NBIX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported a gross profit of 800.70M and revenue of 814.50M. Therefore, the gross margin over that period was 98.3%.
GS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, The Goldman Sachs Group, Inc. reported an operating income of 6.49B and revenue of 17.23B, resulting in an operating margin of 37.7%.
NBIX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported an operating income of 193.40M and revenue of 814.50M, resulting in an operating margin of 23.7%.
GS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, The Goldman Sachs Group, Inc. reported a net income of 5.63B and revenue of 17.23B, resulting in a net margin of 32.7%.
NBIX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported a net income of 197.90M and revenue of 814.50M, resulting in a net margin of 24.3%.
Frequently Asked Questions
GS and NBIX have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GS has higher volatility (11.84%) compared to NBIX (9.63%). In terms of maximum drawdown, GS dropped -78.84% vs NBIX's -97.21%.
GS currently has the higher Sharpe Ratio (2.59 vs 0.89), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GS and NBIX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer